Position in ALKS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$148,512,000
+$49,183,000 QoQ
Shares Held
4,200,000
+18.3% QoQ
Ownership
2.52%
of shares outstanding
% of Portfolio
8.59%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Commodore Capital LP holds $227,047,000 across 2 Drug Manufacturers - Specialty & Generic names. ALKS ranks #1 (65.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALKS |
Alkermes plc.
This page
|
4,200,000 | $148,512,000 | |
| 2 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
5,650,000 | $78,535,000 |
All Filings in ALKS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $148,512,000 | 4,200,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $99,329,000 | 3,550,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $92,902,620 | 3,096,754 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $70,094,500 | 2,450,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $64,389,000 | 1,950,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $66,148,000 | 2,300,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $81,171,000 | 2,900,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $33,137,500 | 1,375,000 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||